Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
Price : $35 *
At a glance
- Drugs Lisdexamfetamine (Primary) ; Fluoxetine
- Indications Mood disorders
- Focus Therapeutic Use
- 03 Nov 2016 Status changed from recruiting to completed.
- 11 Jan 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
- 11 Jan 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.